<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166511">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920698</url>
  </required_header>
  <id_info>
    <org_study_id>2013.798</org_study_id>
    <nct_id>NCT01920698</nct_id>
  </id_info>
  <brief_title>Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation</brief_title>
  <acronym>MITRA-FR</acronym>
  <official_title>Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to compare the safety, the efficacy and the
      cost-effectiveness of 2 therapeutic strategies (optimal standard of care therapy alone
      versus percutaneous MitraClip procedure and optimal standard of care therapy) in patients
      with severe secondary mitral regurgitation.

      This trial is a French, multicenter and randomized trial. Patients enrolled will be
      clinically followed for 2 years (phone call at 1 month, clinical visit at 6 months, 12
      months and 24 months).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause mortality and unplanned hospitalizations for heart failure</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality, cardiac mortality</measure>
    <time_frame>30 days, 6 months, 12 months, and 24 months.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival with no major cardiovascular events</measure>
    <time_frame>30 days, 6 months, 12 months, and 24 months.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>30 days, 6 months, 12 months and 24 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any serious adverse events cardiovascular or not occurring within each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life score as measured by the European Quality of Life-5 Dimensions instrument.</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional evaluation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic evaluation between baseline and 6 and 12 months.</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers (BNP levels, creatinine) at 6 months and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of each strategy at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cost-effectiveness of each therapeutic strategy will be assessed by the evaluation of medical costs linked to the pathology (hospitalizations, consultations, and external medical costs (biology, radiology, medications) and compared in the 2 groups during the first 12 months of follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>MitraClip Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to the Control group will receive optimal therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous MitraClip Device Implantation</intervention_name>
    <description>MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system</description>
    <arm_group_label>MitraClip Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <other_name>Patients randomized to the Control Group will receive optimal medical therapy alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Severe secondary mitral regurgitation confirmed by the Echocardiography Core
             Laboratory

          -  Characterized by a regurgitation volume &gt; 30 mL/beat and a regurgitant orifice area &gt;
             20 mm2

          -  New York heart Association Class≥ II.

          -  Left ventricular ejection fraction between 15% and 40%

          -  Minimum of 1 hospitalization for heart failure within 12 months preceding
             randomization

          -  Assessed by the investigator to be on optimal standard of care therapy for heart
             failure

          -  Assessed by the heart team to be not eligible to a mitral surgery intervention

        Exclusion Criteria:

          -  Primary mitral regurgitation

          -  Myocardial infarction or coronary bypass grafting surgery within 3 months prior to
             randomization

          -  Cardiac resynchronization therapy within 3 months prior to randomization

          -  Need for any cardiovascular surgery (including registration on cardiac transplant
             list)

          -  Coronary angioplasty within 1 month prior to randomization

          -  History of mitral valve repair

          -  Active infection requiring current antibiotic therapy

          -  Terminal renal insufficiency (renal replacement therapy)

          -  Severe hepatic insufficiency

          -  Evidence of stroke within 3 months prior to randomization

          -  Concurrent medical condition with a life expectancy of less than 12 months

          -  Uncontrolled hypertension

          -  Known hypersensitivity to nitinol

          -  Currently participating in another trial

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JEAN FRANCOIS OBADIA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JEAN FRANCOIS OBADIA, MD</last_name>
    <phone>472357247</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-francois.obadia@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan MEWTON, MD</last_name>
    <phone>427856687</phone>
    <phone_ext>+33</phone_ext>
    <email>nathan.mewton@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu de Besancon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SYDNEY CHOCRON, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Sydney Chocron, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LIONEL LEROUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>LIONEL LEROUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN FRANCOIS OBADIA, MD</last_name>
    </contact>
    <investigator>
      <last_name>JEAN FRANCOIS BADIA, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>EMMANUEL TEIGER</last_name>
    </contact>
    <investigator>
      <last_name>EMMANUEL TEIGER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis Robinson</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CHRISTOPHE CAUSSIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>CHRISTOPHE CAUSSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ALAIN PRAT, PR</last_name>
    </contact>
    <investigator>
      <last_name>ALAIN PRAT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN LOUIS BONNET, Pr</last_name>
    </contact>
    <investigator>
      <last_name>FREDERIC COLLART, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>THIERRY LEFEVRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>THIERRY LEFEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FLORENCE LECLERCQ, PR</last_name>
    </contact>
    <investigator>
      <last_name>FLORENCE LECLERCQ, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Du Millenaire</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CHRISTOPHE PIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>CHRISTOPHE PIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YVES JUILLIERE, PR</last_name>
    </contact>
    <investigator>
      <last_name>YVES JUILLIERE, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PATRICE GUERIN, PR</last_name>
    </contact>
    <investigator>
      <last_name>PATRICE GUERIN, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALEC VAHANIAN, PR</last_name>
    </contact>
    <investigator>
      <last_name>ALEC VAHANIAN, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARC BEDOSSA, MD</last_name>
    </contact>
    <investigator>
      <last_name>MARC BEDOSSA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PATRICK OHLMANN, PR</last_name>
    </contact>
    <investigator>
      <last_name>PATRICK OHLMANN, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NICOLAS DUMONTEIL, MD</last_name>
    </contact>
    <investigator>
      <last_name>NICOLAS DUMONTEIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Heart diseases</keyword>
  <keyword>Mitral valve insufficiency</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
